{"filing":{"accession_number":"0001193125-26-336841","cik":"0001776111","ticker":"MBX","company_name":"MBX Biosciences, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"mbx-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526336841/mbx-20260806.htm"},"events":[{"id":25560,"run_id":23201,"accession_number":"0001193125-26-336841","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"MBX Biosciences announced Q2 2026 financial results via press release, reporting R\u0026D expenses of $31.0M (vs. $17.7M YoY), G\u0026A expenses of $9.9M (vs. $4.1M YoY), net loss of $37.1M (vs. $19.4M YoY), and cash position of $418.6M expected to fund operations into 2029.","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26428,"accession_number":"0001193125-26-336841","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"MBX Biosciences announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes quarterly R\u0026D expenses ($31.0M vs. $17.7M YoY), G\u0026A expenses ($9.9M vs. $4.1M YoY), net loss ($37.1M vs. $19.4M YoY), and cash position ($418.6M expected to fund operations into 2029). This is a standard quarterly earnings release with financial statements data, meeting the definition of earnings_release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:55:08.692877+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26429,"accession_number":"0001193125-26-336841","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure furnishes a press release (EX-99.1) titled \"MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights,\" which reports Q2 2026 financial results including R\u0026D expenses ($31.0M vs. $17.7M YoY), G\u0026A expenses ($9.9M vs. $4.1M YoY), and net loss ($37.1M vs. $19.4M YoY), along with cash position ($418.6M) and operational milestones. This is a standard earnings release disclosure, material to investors assessing the company's financial performance and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:55:08.692877+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25561,"run_id":23201,"accession_number":"0001193125-26-336841","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"MBX Biosciences provided a clinical trial progress update for MBX 4291, a Phase 1 obesity candidate, confirming the company remains on track to report 12-week MAD (multiple ascending dose) data in Q4 2026.","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26430,"accession_number":"0001193125-26-336841","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The Item 8.01 disclosure centers on a clinical trial progress update for MBX 4291, a Phase 1 obesity candidate, confirming the company remains on track to report 12-week MAD data in Q4 2026. While the supplemental press release (EX-99.1) also reports Q2 2026 financial results and executive appointments, the Item 8.01 itself is narrowly focused on the clinical development milestone. This is an operational/strategic event—advancement of a pipeline program—rather than an earnings release, executive change, or other specific event type. The update is material to investors assessing the company's R\u0026D progress and pipeline execution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:55:08.692877+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26428,"accession_number":"0001193125-26-336841","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"MBX Biosciences announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes quarterly R\u0026D expenses ($31.0M vs. $17.7M YoY), G\u0026A expenses ($9.9M vs. $4.1M YoY), net loss ($37.1M vs. $19.4M YoY), and cash position ($418.6M expected to fund operations into 2029). This is a standard quarterly earnings release with financial statements data, meeting the definition of earnings_release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:55:08.692877+00:00","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-08-06"},{"id":26429,"accession_number":"0001193125-26-336841","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure furnishes a press release (EX-99.1) titled \"MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights,\" which reports Q2 2026 financial results including R\u0026D expenses ($31.0M vs. $17.7M YoY), G\u0026A expenses ($9.9M vs. $4.1M YoY), and net loss ($37.1M vs. $19.4M YoY), along with cash position ($418.6M) and operational milestones. This is a standard earnings release disclosure, material to investors assessing the company's financial performance and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:55:08.692877+00:00","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-08-06"},{"id":26430,"accession_number":"0001193125-26-336841","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The Item 8.01 disclosure centers on a clinical trial progress update for MBX 4291, a Phase 1 obesity candidate, confirming the company remains on track to report 12-week MAD data in Q4 2026. While the supplemental press release (EX-99.1) also reports Q2 2026 financial results and executive appointments, the Item 8.01 itself is narrowly focused on the clinical development milestone. This is an operational/strategic event—advancement of a pipeline program—rather than an earnings release, executive change, or other specific event type. The update is material to investors assessing the company's R\u0026D progress and pipeline execution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:55:08.692877+00:00","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-08-06"}]}